The first case report was published by Imamura et al. in 2021 and described a patient with renal anemia complications who received daprodustat for 6 months for the management of heart failure with preserved ejection fraction; Hb was reported to improve from 8.8 to 10.4 g/dL and B-type natriuretic peptide from 276 to 122 pg/mL [9]. This evidence concerns the gene GSTM1 and heart failure.